Study of VZV-specific immune response induced by intradermal injection of Varicella vaccine

Study of VZV-specific immune response induced by intradermal injection of Varicella vaccine - Study of intradermal injection of Varicella vaccine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020913

Enrollment

150

Registered

2016-02-08

Start date

2015-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy adult

Interventions

SC injection of VZV vaccine ID injection of VZV vaccine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: criteria of live vactine

Exclusion criteria

Exclusion criteria: excluding criteria: patients with acute conditions; patients with underlying diseases, malignant disease, autoimmune diseases, and renal failure with serum creatinine greater than 2; smoker; treated with steroid, immunosuppressant drugs or antiplatelet drugs; with allergic reaction against varicella vaccine or pneumococcal vaccine; dermatological disorder unable to judge if skin test reaction or not; herpes zoster patients.

Design outcomes

Primary

Measure	Time frame
enhancement of CMI VZV-skin test reaction 6W,1Y,2Y 3Y after injection	—

Secondary

Measure	Time frame
antibody titer safety	—

Countries

Japan

Contacts

Public ContactNishimura Yuki

Nara Medical Univ Dept of Dermatology

yukin@naramed-u.ac.jp0744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026